Skip to main content

ICLR · Icon PLC

Track ICLR — free
$186.76 -3.61 (-1.89%)
Market Cap
$13.78B
Shares
74.92M
Volume · Nov 20 351.63K Avg daily vol (3M) 977.37K

Price & Indicators

 

Key stats

Close
$190.36
Thu 19 Nov
Open
$194.26
Thu 19 Nov
Average volume, 30 days
1.1M
shares a session
Short interest
2.4M
3.2% of shares · 1.7 days to cover
Day range
$190.22$199.59
Open $194.26 Close $190.36
52-week closing range
$80.08$215.48
Close $190.36 11.7% under the high
Short volume, last session
35%
Last earnings
Oct 28, 2026
Price history
Jan 2020 to Nov 2026

Up next

Dec 3, 2026 Est · unconfirmed · in 2 wks

Latest documents

2026
Nov 10
Current report 6-K
Executives to present at Jefferies, participate at Evercore

ICON plc CEO Barry Balfe and CFO Nigel Clerkin will present at the Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 12:30pm GMT; Balfe will participate at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:20pm ET.

Source passage
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that Mr. Barry Balfe, CEO of ICON plc, and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 at 12:30pm GMT and Mr. Barry Balfe, CEO of ICON plc, will participate at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:20pm ET. Open the document at this passage
Oct 28
Earnings call
Record $3.15 billion net business wins, book-to-bill 1.56 times

ICON reported record net business wins of $3.15 billion, up 51% year-over-year, with a net book-to-bill of 1.56 times. Revenue was just over $2 billion, down 2.9% year-over-year, while adjusted EBITDA rose 3% to $337 million and adjusted EPS was $2.66. The board approved a new $750 million share repurchase authorization.

Read from the first part of this long document
5 source passages
Consequently, net business wins were a record $3.15 billion, up 51% year-over-year, yielding a net book-to-bill of 1.56 times. Revenue in quarter three was just over $2 billion, representing a year-on-year decrease of 2.9%, or a decrease of 2.5% on a constant currency basis. Adjusted EBITDA increased 3% to $337 million, expanding adjusted EBITDA margin by 70 basis points to 16.6%. Adjusted net Net income for the quarter was $206 million, equating to adjusted earnings per share of $2.66, a sequential increase of 4%. In addition, our board approved a new $750 million share repurchase authorization, underscoring our confidence in the business and our ongoing commitment to shareholder returns. Open the document at this passage
Oct 27
Current report 6-K
Issued $2.15 billion senior notes and repaid secured debt in August 2026

ICON plc sold $2.15 billion of senior unsecured notes on August 13, 2026 through its subsidiary ICON Investments Six Designated Activity Company, and used the proceeds to repay the $900.0 million Senior Secured Term Loan, redeem the $750.0 million May 2027 Notes, and repay the $500.0 million Bridge Secured Credit Facility. The Board also raised the share buyback authorization to $750.0 million on October 20, 2026.

Read from the first part of this long document
3 source passages
On August 13, 2026, ICON Investments Six Designated Activity Company (the “Issuer”), a wholly-owned subsidiary of ICON plc, sold and issued $2.15 billion of senior unsecured notes The Company applied the net proceeds from the issuance to, (i) on August 13, 2026, repay all the outstanding Senior Secured Term Loan of $900.0 million, (ii) on August 14, 2026, redeem, in full, the outstanding May 2027 Notes of $750.0 million, and (iii) on August 17, 2026, repay all outstanding borrowings under the Bridge Secured Credit Facility of $500.0 million. On October 20, 2026, the Board of Directors of the Company ("Board") approved an increase in the share buyback authorization, bringing the total amount available for repurchases under the program up to $750.0 million. Open the document at this passage
Oct 27
Current report 6-K
Q3 revenue falls 2.9% to $2,024.8 million; guidance updated

ICON plc reported third-quarter 2026 revenue of $2,024.8 million, a decrease of 2.9% on quarter three 2025, and GAAP net income of $122.1 million. It updated full-year 2026 guidance, with revenue expected in the range of $8,100 - $8,200 million. Adjusted diluted earnings per share guidance is in the range of $10.35 - $10.65.

6 source passages
Revenue for the third quarter was $2,024.8 million. This represents a decrease of 2.9% on quarter three 2025, GAAP net income was $122.1 million, resulting in diluted earnings per share of $1.58 in quarter three 2026 Updating 2026 full-year financial guidance issued with revenue expected in the range of $8,100 - $8,200 million and adjusted diluted earnings per share expected in the range of $10.35 - $10.65. Open the document at this passage
Oct 8
Current report 6-K
Current report

ICON plc will release third quarter 2026 financial results after market close on Tuesday, October 27, 2026, then discuss performance on a conference call and webcast on Wednesday, October 28, 2026 at 8:00am ET.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.23B
Trailing 12 months
Net income (TTM)
$448.66M
Trailing 12 months
Revenue growth YoY
-2.9%
Year over year
Operating margin
8.7%
Trailing 12 months
P / E (TTM)
32.3
Trailing earnings · reciprocal yield 3.1%
FCF yield
6.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+19.9%
Trailing year
Short interest
3.2%
Latest settlement · 1.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +29%
above
Price vs 50-day avg +5%
above
RSI (14) 48
neutral
MACD trend Negative
52-week position 81%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +38%
trailing
YTD return +4%
this year
Relative strength +44%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $181 › 200d $147 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +45 funds added
Insider flow Distributing
Net -$6.5M over 90 days · 100% sells
Short interest Falling
3.17% of shares out · ▼ -20.0% MoM · 1.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
427 holders — near 3-yr low, contrarian setup
Squeeze score 47
elevated · 0–100
Fundamentals
Strong
Revenue growth +20%
Y/Y
EPS growth −67%
Y/Y
Free cash flow $862.0M
Valuation P/E 31.2
below peers
Buyback $750.0M
remaining
Balance sheet $2.8B
net debt
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −61%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the Earnings Call filed Jun 24, 2026
Revenue · full year 2026 $7.85B – $8.15B
prior FY $8.25B midpoint −3.0% Y/Y
Adjusted diluted earnings per share · full year 2026 Non-GAAP $10.00 – $11.00
Guided vs delivered · last 5 settled
Full year revenue full year
guided $8.05B – $8.1B
$8.25B Beat +2.2%
Revenue guidance 2021
guided $5.43B – $5.53B
$5.48B In line
2020 revenue 2020
guided $2.75B – $2.81B
$2.8B In line
Earnings per share 2020
guided $6.00 – $6.50
$6.15 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+29% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
81% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $181 › 200d $147 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +45 funds added
Insider flow Distributing
Net -$6.5M over 90 days · 100% sells
Short interest Falling
3.17% of shares out · ▼ -20.0% MoM · 1.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
427 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $80 Now $190 · 81% Range high $215
vs 200-day avg +29% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ICLR
Icon PLC
this stock
$13.78B +4.5% +19.8% 31.2 3.2%
TMO
Thermo Fisher Scientific Inc.
$255.19B +18.9% +14.5% 36.3 1.3%
DHR
Danaher Corp
$160.10B -0.6% +8.5% 37.2 1.2%
IDXX
Idexx Laboratories Inc
$54.33B +1.9% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$49.43B +28.9% +6.4% 34.5 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
427
% held
101.8%
Net QoQ
-4.0M sh
Top holder
Artisan Partners Limited…
Held Float
View
Held by Funds
Fund positions
133
View
Short & Settlement
Short Interest Falling
Shares short
2.4M
Days to cover
1.7d
Change
-594.1K sh
View
Short Volume
Short vol %
35%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
4.8K
Value
$821.8K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
45.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$6.5M
Buyers / Sellers
0 / 7
Buyers Sellers
View
Congressional Trades Sell
Member
Kevin Hern
Amount
$15.0K–$50.0K
Traded
Aug 14, 2026
View
Financials
Financials
Revenue (FY)
$8.3B
Net income (FY)
$229.3M
EPS diluted
$2.90
View
Buybacks
Authorized
$750.0M
Remaining
$750.0M
Spent Remaining
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 10, 2026
This year
24

ICON plc CEO Barry Balfe and CFO Nigel Clerkin will present at the Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 12:30pm GMT; Balfe will participate at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:20pm ET.

View
Proposed Sales
Value
$2.0M
Shares
10.0K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
ICON to Participate at Upcoming I…
Published
Nov 10, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ICLR -5.1% +2.7% +37.9% -9.9% +4.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.4% +9.0% +43.5% -4.7% -0.5%

Capital returns

Buyback program · as of Oct 27, 2026
Authorized
$750.00M
Spent (derived)
$0
Remaining
$750.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1060955 CUSIP G4705A100 13F (30d) 438 filings 393 filers Visit website Investor relations